| | | | |
| | | Operative date for treatment or services received |
| | | Maximum amount that may be withdrawn |
|
| | | | |
| (a) | External radiotherapy (except hemi-body radiotherapy) |
|
| | | For course of treatment beginning before 1 June 1997 |
| | | $60 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | For course of treatment beginning on or after 1 June 1997 |
| | | $80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (b) | Brachy-therapy with external radiotherapy |
|
| | | For course of treatment beginning before 1 June 1997 |
| | | $150 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | For course of treatment beginning on or after 1 June 1997 but before 1 March 2021 |
| | | $300 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | For course of treatment beginning on or after 1 March 2021 |
| | | $360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (c) | Brachy-therapy without external radiotherapy |
|
| | | For course of treatment beginning before 1 June 1997 |
| | | $300 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | For course of treatment beginning on or after 1 June 1997 |
| | | $360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | For course of treatment beginning on or after 1 July 1990 but before 1 March 2021 |
| | | $30 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (e) | Stereotactic radiotherapy for cancer |
|
| | | For course of treatment beginning on or after 1 November 1999 |
| | | $2,800 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (f) | Hemi-body radiotherapy |
|
| | | For course of treatment beginning on or after 1 March 2021 |
| | | $80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (g) | Proton beam therapy for a Category 1 clinical indication listed in the Approved Indications for PBT |
|
| | | For course of treatment beginning on or after 1 October 2022 |
| | | $80 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (h) | Proton beam therapy for a Category 2 clinical indication listed in the Approved Indications for PBT |
|
| | | For course of treatment beginning on or after 1 October 2022 |
| | | $360 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (i) | Proton beam therapy for a Category 3 clinical indication listed in the Approved Indications for PBT |
|
| | | For course of treatment beginning on or after 1 October 2022 |
| | | $2,800 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 2. | [Deleted by S 523/2009 wef 01/11/2009] |
|
|
| 3. | Treatment of neoplasms by chemotherapy |
|
| | | With effect from 1 November 2015 but before 1 September 2022 |
| | | $1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 4. | Anti-retroviral drugs registered in Singapore for the medical treatment of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) |
|
| | | With effect from 1st June 2001 |
| | | $550 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 5. | [Deleted by S 770/2022 wef 01/10/2022] |
|
| | | | |
| 6. | Blood transfusions and desferrioxamine for the medical treatment of thalassaemia |
|
| | | With effect from 1 June 1999 but before 1 November 2020 |
| | | $350 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | With effect from 1 November 2020 |
| | | $550 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 7. | Hyperbaric oxygen therapy |
|
| | | With effect from 1st March 2002 |
| | | $100 per treatment or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 8. | Intravenous antibiotic infusion at approved hospitals as designated by the Minister of Health |
|
| | | 1 October 2002 to 30 June 2017 (both dates inclusive) |
| | | $600 per weekly cycle subject to a maximum claim of $2,400 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 9. | Rental of devices for long term oxygen therapy and infant continuous positive airway pressure therapy |
|
| | | With effect from 1 October 2002 but before 1 November 2020 |
| | | $75 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| | | With effect from 1 November 2020 |
| | | $150 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 10. | Immunosuppressants for organ transplant |
|
| | | With effect from 1st January 2006 |
| | | $300 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 11. | Cancer scan or diagnostic test |
|
| | | With effect from 1 April 2008 but before 1 September 2022 |
| | | $600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 12. | Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test |
|
| | | With effect from 1 September 2022 |
| | | $600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| 13. | Approved cancer drug administered for the treatment of neoplasms: |
|
| | | | |
| (a) | where only approved cancer drugs listed in the first tier of the CDL are administered in a month |
|
| | | With effect from 1 September 2022 |
| | | $600 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (b) | where only approved cancer drugs listed in the second tier of the CDL are administered in a month |
|
| | | With effect from 1 September 2022 |
| | | $1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|
| (c) | where approved cancer drugs listed in both the first tier and the second tier of the CDL are administered in a month |
|
| | | With effect from 1 September 2022 |
| | | $1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower. |
|